AZD5438 is primarily investigated for its potential in cancer therapy, particularly as a cyclin-dependent kinase (CDK) inhibitor. It targets CDK1, CDK2, and CDK9, which are crucial for cell cycle regulation and transcription. By inhibiting these kinases, AZD5438 can induce cell cycle arrest and apoptosis in cancer cells, making it a promising candidate for treating various malignancies. Research has explored its efficacy in breast cancer, ovarian cancer, and other solid tumors, often in combination with other chemotherapeutic agents to enhance treatment outcomes. Additionally, its role in overcoming drug resistance in certain cancers is under study, offering hope for more effective therapeutic strategies.